Compare Neurocrine Biosciences Inc (NBIX) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Rivian Automotive, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155.7 (market cap $15.77B), while Rivian Automotive, Inc. trades at $15.95 (market cap $23.17B). The key difference: Rivian Automotive, Inc. is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| NBIX | RIVN | |
|---|---|---|
Market Cap | $15.77B | $23.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $22.45 |
52-Week Low | $123.10 | $12.50 |
Enterprise Value | $15.78B | $23.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
Rivian Automotive (RIVN) trades at $16.17, up 2.73% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $5.39B in 2025, with net losses narrowing to -$3.65B, reflecting improving margins. Recent news highlights strong R2 demand and production ramp-up, while cash flow trends show reduced operational losses. Analyst consensus is a Buy with a $18.70 price target, though the stock faces execution risks amid competitive EV market dynamics.
Outlook: Rivian's R2 launch and cost-cutting efforts present growth potential, but persistent losses and high cash burn require careful monitoring. Risks include production scalability and macroeconomic pressures, while institutional sentiment remains cautiously optimistic given the 48% Buy rating from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
